29 Curing HIV infection will require the elimination of a reservoir of infected CD4 + T-cells that persists 30 despite HIV-specific cytotoxic T-cell (CTL) responses. While viral latency is a critical factor in this 31 persistence, recent evidence also suggests a role for intrinsic resistance of reservoir-harboring cells 32 to CTL killing. This resistance may have contributed to negative outcomes of clinical trials, where 33 pharmacologic latency reversal has thus far failed to drive reductions in HIV reservoirs. Through 34 transcriptional profiling, we herein identified over-expression of the pro-survival factor BCL-2 as a 35 distinguishing feature of CD4 + T-cells that survived CTL killing. We show that the inducible HIV 36 reservoir was disproportionately present in BCL-2 hi subsets, in ex vivo CD4 + T-cells. Treatment with 37 the BCL-2 antagonist 'ABT-199' alone was not sufficient to drive reductions in ex vivo viral reservoirs, 38 when tested either alone or with a latency reversing agent (LRA). However, the triple combination 39 of strong LRAs, HIV-specific T-cells, and a BCL-2 antagonist uniquely enabled the depletion of ex 40 vivo viral reservoirs. Our results provide rationale for novel therapeutic approaches targeting HIV 41 cure and, more generally, suggest consideration of BCL-2 antagonism as a means of enhancing CTL 42 immunotherapy in other settings, such as cancer.
Introduction 45 5
To identify candidate mechanisms that may confer CTL resistance to HIV reservoir harboring cells, we 104 first studied differential intrinsic sensitivities to CTL killing in primary CD4 + T-cells. Given that different 105 maturational phenotypes of CD4 + T-cells are associated with differential susceptibilities to CTL (24), we 106 sought to minimize this variable by synchronizing target cells in a central memory (TCM) phenotype, as 107 these cells preferentially harbor the latent reservoir (41). This was achieved following the protocol used to 108 generate cells for the 'cultured TCM model' of HIV latency (see Supplementary Methods) (42, 43) . TCM cells 7 pulsed with various concentrations of its cognate peptide, and measuring BCL-2 expression levels in 156 surviving CD4 + T-cell ( Fig. 2A-B) . We observed significant losses in viable CD4 + T-cells with increasing 157 peptide concentrations (10µg/mL peptide vs NoTx, 3.2-fold decrease p<0.0001; 2.1-fold decrease vs 158 0.01µg/mL peptide, p<0.0001, Fig. 2C) , and a corresponding increase in BCL-2 expression in the 159 remaining CD4 + T-cells (10µg/mL vs NoTx, p=0.008; vs 1µg/mL, p=0.03, Fig. 2C&D ). This effect was 160 confirmed by assessing the impact of CTL killing on total numbers of target cells as divided into BCL-2 hi 161 and BCL-2 lo populations ( Fig. 2E) . We observed a progressive decrease in the numbers of BCL-2 lo cells 162 with increasing peptide concentrations (mean count -83,000 at 0.01µg/mL peptide vs. 45,000 at 10µg/mL 163 peptide, p=0.009, Fig. 2E) , alongside a lack of significant change in the numbers of BCL-2 hi cells, even at 164 10µg/mL of RR11 peptide ( Fig. 2E) . Thus, these data support that the natural heterogeneity of BCL-2 165 expression within ex vivo CD4 + T-cells is sufficient to influence susceptibility to CTL killing, with BCL-166 2 hi cells exhibiting preferential survival. This association could either reflect differences across maturational 167 phenotypes -where, for example, naïve CD4 + T-cells may both express lower levels of BCL-2 and be more 168 susceptible to CTL killing -or, may also reflect heterogeneity of these parameters within a given phenotype.
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To distinguish between these, we performed a similar killing assay as in Fig. 2E , with the addition of 170 phenotypic marker staining to discriminate naïve -CD45RA + CCR7 + , central memory (CM) -CD45RA -171 CCR7 + , and effector memory (EM) -CD45RA -CCR7populations. Parallel experiments were performed 172 where cells were either activated with anti-CD3/anti-CD28 prior to peptide pulsing and co-culture, or were 173 peptide pulsed without prior activation. We observed the preferential survival of BCL-2 hi cells within each 174 of these populations, whether or not cells had been activated (Fig. 2F) . The most pronounced skewing in 175 BCL-2 expression was observed within the TEM cells ( Fig. 2F) , which corresponded with a greater degree 176 of killing of this population (%killed at 5 µg/ml peptide by phenotype: TCM -21.7%, TEM -63.9%, naïve -177 36.8%). Thus, even within a given maturational population, the relative expression of BCL-2 is associated 178 with susceptibility to elimination by CTL. 8 The Reactivatable HIV Reservoir is Preferentially Harbored in BCL-2 hi Cells in Individuals on Long-Term 181 ART 182 183 Given the above observations that BCL-2 hi cells preferentially resist killing by CTL, we next probed a 184 potential role for this mechanism in the persistence of the HIV reservoir. We first assessed BCL-2 185 expression levels in ex vivo CD4 + T-cells from ART-suppressed donors, following latency reversal with 186 PMA/Ionomycin (PMA/I) (Fig. 3A) . This was accomplished using a recently developed flow cytometry 187 technique which allows for the identification and phenotypic characterization of this extremely rare 188 population (44). We established a gating strategy using cells from an ART-naïve, chronically HIV-positive 189 individual ('OM5374') and an HIV-negative donor ('OM6960') ( Fig. 3A) . As expected, we observed a 190 lack of Gag + cells in the HIV-negative sample, contrasted by a detectable population in the HIV-positive 191 sample, which was enhanced by PMA/I stimulation.
193
We extended this assay to measure differences of BCL-2 expression levels between HIV-infected and 194 uninfected cells amongst ex vivo CD4 + T-cells from 6 additional durably ART-suppressed study participants 195 (Table 1) . We observed extremely rare HIV-infected populations from each participant following PMA/I 196 stimulation, while no Gag + events were observed in unstimulated cells ( Fig. 3B) . For each individual, HIV-197 Gag + populations were found to express higher levels of BCL-2 (MFI 2874, range: 1460-5820) than 198 corresponding Gagpopulations (MFI 1215, range: 1100-1320) (p=0.01, Fig. 3C-D) . In contrast to these 199 ART-suppressed individuals, we observed similar BCL-2 expression levels between the Gag + (MFI mean: 200 1,001, range: 965-1,450) and Gagcell populations (MFI mean: 1,007, range: 1,093-1,350) from 4 ART-201 naïve participants (Table 2) , following PMA/I stimulation ( Fig. 3E-F) . Although we acknowledge inherent 202 limitations of analyzing such very rare events, we draw confidence in our conclusion from the observation 203 that this difference was statistically robust across a cohort of 6 individuals (p=0.016, Fig. 3D ). Thus, we 204 observed that, following reactivation, the HIV reservoir in ART-suppressed individuals capable of 205 producing Gag is preferentially present in BCL-2 hi cells. This suggests that the levels of BCL-2 over-206 9 expression from ARV-treated individuals are not simply the result of HIV expression, but rather may be a 207 feature that is enriched in cells comprising long-lived HIV reservoirs.
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As an additional method for assessing the BCL-2 expression profile of reservoir-harboring cells, we sorted 210 ex vivo CD4 + T-cells from long-term ART-suppressed individuals into BCL-2 hi and BCL-2 lo populations 211 by flow cytometry, and quantified HIV DNA in each population. HIV DNA was measured using a recently 212 developed droplet digital PCR method that allows for the discrimination of relatively intact proviruses, 213 which contain binding sites for both gag and env primer/probe pairs (45). We observed significantly higher 214 frequencies of HIV proviruses in BCL-2 hi CD4 + T-cells, compared to BCL-2 lo population (p=0.02 for "intact" 215 and total gag) ( Fig. 4A) . We next determined whether this enrichment of infected cells in the BCL-2 hi 216 subset was reflective of differences across maturational populations, or whether BCL-2 hi cells would be 217 enriched for infected cells even within a given memory population. We included the maturational markers 218 CCR7 and CD45RA in our flow cytometry panel, and sorted cells from two donors into BCL-2 hi and BCL-219 2 lo subsets for each: of naïve -CD45RA + CCR7 + , central memory (CM) -CD45RA -CCR7 + , and effector 220 memory (EM) -CD45RA -CCR7populations ( Fig. 4B) . For both individuals, we observed pronounced 221 enrichments of "intact" HIV DNA in the BCL-2 hi vs BCL-2 lo populations. These patterns were also reflected 222 at the level of total HIV DNA in each memory subset ( Fig. 4C) . These data provide an additional line of 223 evidence supporting that the HIV reservoir is preferentially harbored in BCL-2 hi cells in individuals on 224 long-term ART, and indicate that this is not merely reflective of differences across maturational phenotypes.
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BCL-2 Antagonist ABT-199 Fails to Reduce Either Total HIV DNA or Infectious Reservoirs from ex vivo
CD4 + T-cells from ARV-Treated Donors, but can Drive Reductions in a Primary Cell Latency Model
229
A previous study reported that the combination of ABT-199 with anti-CD3/anti-CD28 antibodies was 230 sufficient to drive reductions in the frequencies of HIV-infected cells taken ex vivo from ART-suppressed 231 participants (46) . However, this was not associated with reductions in the amounts of HIV RNA released 10 into culture supernatants, and the effect on the inducible infectious reservoir as measured by QVOA was 233 not tested. As a prelude to assessing the abilities of ABT-199 to sensitize HIV reservoir-harboring cells to 234 elimination by CTL, we therefore determined whether this agent had activity against latently HIV-infected 235 cells when used either alone, or in combination with a LRA.
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In our experiments, the effects of BCL-2 antagonist ABT-199 were assessed using an HIV eradication 238 (HIVE) assay ( Fig. 5A) , where changes in infected cells are measured by both droplet digital PCR (ddPCR) 239 to measure total frequencies of infected cells (total HIV DNA), and QVOA to measure replication 240 competent reservoirs (infectious units). This distinction is important as, in ex vivo CD4 + T-cells from ARV-241 treated individuals, the large majority of HIV DNA represents defective proviruses with no potential for 242 viral replication (47). In our HIVE assays, we focused on the protein kinase C agonist bryostatin-1 as the 243 LRA, as we had observed that it mitigated the appreciable levels of non-specific CD4 + T-cell toxicity 244 induced by ABT-199 ( Fig. S2) . Potent activation of CD4 + T-cells by bryostatin-1 was confirmed by CD69 245 staining ( Fig. S3 ). We were careful to account for cell death in our QVOAs by counting only viable CD4 + 246 T-cells by flow cytometry following a 24-hour drug wash-out period to calculate infectious units per million 247 CD4 + T-cells (IUPM). We further confirmed that prior treatment with ABT-199 did not continue to 248 negatively affect viability after the 24-hour wash-out, which may have otherwise introduced inaccuracy 249 into our QVOA measurements ( Fig. S4) . DNAse I was also included in the HIVE co-culture medium to 250 degrade the genomes of killed target cells such that these would not be measured by ddPCR.
252
We first tested whether ABT-199 would drive reductions when targeting 'natural' HIV reservoirs in ex vivo 253 CD4 + T-cells from ART-suppressed donors. A representative example of a HIVE assay is shown in Fig. 
254
5B. We did not observe reductions in either HIV DNA or IUPM following treatment with ABT-199 (1µM 255 or 100nM), either alone or in combination with bryostatin-1 ( Fig. 5B) . In this initial experiment, the overall 11 by QVOA. The only significant differences that we observed were increases in IUPM following treatment 258 with bryostatin-1 alone (p<0.001, Fig. 5B ). We extended this HIVE assay to a total of 8 ARV-treated donors, 259 and consistently observed a lack of significant differences in either HIV DNA or IUPM between untreated 260 conditions and ABT-199 (both 1µM and 100nM), tested either alone or in combination with bryostatin-1 261 ( Fig. 5C-D) . In contrast, the increases in IUPM observed with bryostatin-1 treatment were found to be 262 consistent across this population (p<0.01 at 1µM, and p=0.03 at 100nM, 
Reductions in HIV Reservoirs from ex vivo CD4 + T-cells
286
In our hands, both combinations of LRA+ABT-199 and of LRA+CTL were individually effective against 287 primary cell latency models, but not against ex vivo reservoirs. We therefore next tested the central 288 hypothesis of the current study, that a combination of these treatments would deplete ex vivo reservoirs as 289 a result of ABT-199 counteracting resistance to CTL-mediated elimination (Fig. 6A) . In an initial 290 experiment, using cells from an ARV-treated donor 'OM5011' (see Table 1 ), we continued to utilize 291 bryostatin-1 as an LRA, and measured the elimination of latently-infected cells with ddPCR -quantifying 292 HIV DNA at both gag and env amplicons. Using two different autologous HIV-Gag-specific CTL clones 293 (targeting the ACQGVGGPGHK 'AK11' and the HPVHAGPIA 'HA9' epitopes), we observed significant 294 depletions in HIV DNA as measured at the env target sequence uniquely in the triple combination condition 295 of bryostatin-1+Gag-specific CTL+ABT-199 (both p<0.01 respectively, Fig. 6B ). We included an 296 autologous CMV-pp65-specific CTL clone as an additional control, and observed a lack of depletion in 297 HIV DNA, as expected ( Fig. 6B) . Using samples from the same experiment, we observed non-significant 298 trends towards depletion in HIV DNA as measured at the gag target sequence for both CTL conditions 299 (AK11 -p=0.20, HA9 -p=0.15, Fig. 6C ). In a second experiment, we utilized an autologous polyclonal 300 HIV-specific T-cell products that has been developed for T-cell therapy (termed "HSTs") (50, 51). The
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HSTs used in this study ( Fig. 6D&E, and Fig. 7&8 ) exhibited high frequencies of HIV-specific T-cells 302 (IFN-g responses to HIV-Gag/Nef/Pol peptide pools, range: 6970-28,130 SFC/10 6 cells), and they were 303 confirmed to respond to multiple epitopes by ELISPOT and intracellular cytokine staining ( Fig. S6A-C) , 304 and exhibited strong cytotoxicity against peptide-pulsed cells (Fig. S6D) . In this experiment, we observed 305 that the triple combination of bryostatin-1+HSTs+ABT-199 uniquely drove a significant reduction in HIV 306 DNA, as measured by primers and probes targeting gag (Fig. 6D) , however a trend towards a reduction in 307 ddPCR targeting env did not reach statistical significance (p=0.06, Fig. 6E ). While these initial results did 13 provide some support for our hypothesis, we also considered them to be somewhat marginal due to the lack 309 of consistent statistical significance. Given how resource intensive these HIVE assays are (ex. using ~1 x 310 10 9 PBMCs per donor per experiment), we opted to transition to the use of the "maximally activating" LRA 311 anti-CD3/anti-CD28 for HIVE assays, positing that this would enhance our ability to detect an ability of 312 ABT-199 to sensitive reservoir-harboring cells to elimination by kick and kill.
314
We assessed the combination of anti-CD3/anti-CD28, ABT-199, and autologous HSTs in an initial HIVE 315 assay targeting ex vivo CD4 + T-cells from ART-suppressed donor OM5148. The elimination of reservoir-316 harboring cells was measured in parallel by ddPCR, and QVOAs ( Fig. 7A) . We observed significant 317 reductions in total HIV DNA ( Fig. 7B-C) following treatment with anti-CD3/anti-CD28 and HSTs, as well 318 as with anti-CD3/anti-CD28 and ABT-199, and further significant reductions with anti-CD3/anti-
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CD28+HSTs+ABT-199 ( Fig. 7B, 3 .4-fold vs. NoTx, p<0.0001; 2.1-fold vs. anti-CD3/anti-CD28+HSTs, 320 p=0.009; 1.9-fold vs. anti-CD3/anti-CD28+ABT-199, p=0.03). Consistent with our previous work, the 321 decrease in HIV DNA with a maximal LRA+T-cells was not mirrored by a decrease in levels of replication 322 competent provirus as measured by QVOAs. Only by combining ABT-199 with anti-CD3/anti-323 CD28+HSTs, we were able to observe a significant reduction in this infectious reservoir, with no p24 + wells 324 observed in the QVOA (IUPM 0 vs. NoTx:0.66, p=0.02, Fig. 7D ). We next performed an analogous HIVE 325 using an autologous HIV-specific CTL clone targeting a non-escaped HIV epitope, which had previously 326 failed to eliminate 'natural' HIV reservoirs in the absence of ABT-199 (21). As before, treatment with anti-327 CD3/anti-CD28+CTL led to significant 2.1-fold reductions in HIV DNA, while further significant 5.7-fold 328 reductions were observed with anti-CD3/anti-CD28+CTL clone+ABT-199 ( Fig. 7C) . However, significant 329 decreases in IUPM were uniquely observed with the triple combination of anti-CD3/anti-CD28, CTL clones, 330 and ABT-199 (0.32 vs. 2.63 NoTx, p<0.001, Fig. 7E ). Thus, in two initial HIVE assays using either HSTs 331 or a CTL clone, we observed that ABT-199 facilitated reductions in IUPM that were not observed with 332 effectors+LRA without ABT-199. 14 We next tested these treatment conditions in 8 additional HIVE assays, using ex vivo CD4 + T-cells from 7 335 participants. For three HST-based HIVE assays, we also ran separate matched HIVE assays using 336 autologous HIV-specific CTL clones confirmed to target non-escaped epitopes (indicated by red lines, proviruses are not expressed, even following stimulation with maximal LRAs, and thus are unlikely to 425 express antigen in vivo. We suggest that this complexity underlies our observations that -whereas for some 426 individuals only 'intact' proviruses were enriched in BCL-2 hi cells (ex. WWH-B011 in Fig. 4C ), in other 427 individuals a degree of enrichment was also observed for total HIV DNA (mostly defective) ( Fig. 4A) . We 428 also note that whereas BCL-2 antagonism was required to achieve measurable reductions in QVOA assays, 429 it did also further enhance CTL-mediated reductions in total HIV DNA ( Fig. 7B &C) 
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Although Venetoclax has non-trivial side-effects, it is reasonably well-tolerated, with CLL patients often 442 taking this drug for years (72). It is therefore worth considering clinical trials involving BCL-2 antagonist 443 as a possible strategy for reducing or eliminating HIV reservoirs in individuals on long-term ART. As our 444 ex vivo results suggest that the co-ordination of these agents with HIV-specific CTL may be needed to 445 achieve such reductions, it is important to note that ABT-199 did not impair the viability or functionality 
